Skip to main content
SpringerLink
Log in

Structure Toxicity Relationships - How Useful Are They in Predicting Toxicities of New Drugs?

  • Chapter
Book cover Biological Reactive Intermediates VI

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 500))

Abstract

Several new drugs have either been removed from the market soon after their release, or been flagged for careful monitoring and restricted use because of severe toxic effects. Although in some cases the parent drug structure may be responsible for the observed toxicities, in most cases reactive metabolites are formed that interact with cellular macromolecules to stress cells directly, and/or more commonly, yield immunogenic products. Since it is the structures of drugs and their metabolites that dictate reactivity, and not the metabolic pathways themselves, this chapter will focus on what can be empirically learned from comparisons of structures associated with toxic effects and similar structures that are less toxic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Al-Salman, J., Arjomand, H., Kemp, D.G., and Mittal, M., 2000, Hepatocellular injury in a patient receiving rosiglitazone. A case report, Ann. Intern. Med 132:121–124.

    PubMed  CAS  Google Scholar 

  • Alvir, M.J., and Lieberman, J.A., 1994, A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States Experience, J. Clin. Psychopharmacol 14:87–89.

    PubMed  CAS  Google Scholar 

  • Andrade, R.J., Lucena, M.I., Martin-Vivaldi, R., Fernandez, M.C., Nogueras, F., Pelaez, G., Gomez-Outes, A., Garcia-Escaño, M.D., Bellot, U., Hervás, A., Cárdenas, F., Bermudez, F., Romero, M., and Salmerón, J., 1999, Acute liver injury associated with ebrotidine, a new H2-receptor antagonist, J. Hepatology 31:641–646.

    Article  CAS  Google Scholar 

  • Andrade, R.J., Lucena, M.I., Fernández, M.C., Suárez, F., Montero, J.L., Fraga, E., and Hidalgo, F., 1999, Fulminant liver failure associated with flutamide therapy for hirsutism, Lancet 353:983.

    Article  PubMed  CAS  Google Scholar 

  • Assal, F., Spahr, L., Hadengue, A., Rubbici-Brandt, L., and Burkhard, P.R., 1998, Tolcapone and fulminant hepatitis, Lancet 352:958.

    Article  PubMed  CAS  Google Scholar 

  • Bakke, O.M., Wardell, W. M., and Lasagna, L., 1984, Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety, Clin. Pharmacol. Ther 35:559–567.

    Article  PubMed  CAS  Google Scholar 

  • Bakke, O.M. Manocchia, M., de Abayo, F., Kaitin, K.I., and Lasagna, L., 1994, Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective, Clin. Pharmacol. Ther 58:108–117.

    Article  Google Scholar 

  • Balasubramaniam, J., 2000, Nimesulide and neonatal renal failure, Lancet 355:575.

    Article  PubMed  CAS  Google Scholar 

  • Banks, A.T., Zimmerman, H.J., Ishak, K.G., and Harter, J.G., 1995, Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions, Hepatologoy 22:820–827.

    Article  CAS  Google Scholar 

  • Beaune, P., Dansette, P.M., Mansuy, D., Finck, M., Amar, C., Leroux, J.P., and Homberg, J.C., 1987, Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug, Proc. Natl. Acad. Sci. U.S.A 84:551–555.

    Article  PubMed  CAS  Google Scholar 

  • Benedetti, F., Cavallaro, R., and Smeraldi, E., 1999, Olanzapine-induced neutropenia after clozapine-induced neutropenia, Lancet 354:567.

    Article  PubMed  CAS  Google Scholar 

  • Benet, L.Z., Spahn-Langguth, H., Iwakawa, S., Volland, C., Mizuma, T., Mayer, S., Mutschler, E., and Lin, E.T., 1993, Predictability of the covalent binding of acidic drugs in man, Life Sci 53:141–146.

    Article  Google Scholar 

  • Bennett, C.L., Weinberg, P.D., Rozenberg-Ben-Dror, K., Yarnold, P.R., Kwaan, H.C., and Green, D., 1998, Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases, Ann. Intern. Med 128:541–544.

    PubMed  CAS  Google Scholar 

  • Bennett, C.L., Connors, J.M., Carwile, J.M., Moake, J.L., Bell, W.R., Tarantolo, S.R., McCarthy, L.J., Sarode, R., Hatfield, A.J., Feldman, M.D., Davidson, C.J., and Tsai, H.-M., 2000, Thrombotic thrombocytopenic purpura associated with clopidrogel, N. Engl. J. Med 342:1773–1777.

    Article  PubMed  CAS  Google Scholar 

  • Berson, A., Schmets, L., Fisch, C., Fau, D., Wolf, C., Fromenty, B., Deschamps, D., and Pessayre, D., 1994, Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen, J. Pharmacol. Exp. Ther 270: 167 –176.

    PubMed  CAS  Google Scholar 

  • Bluhm, R.E., Adedoyin, A., McCarver, D.G., and Branch, R.A., 1999, Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation as risk factors, Clin. Pharmacol. Ther 65:598–605.

    Article  PubMed  CAS  Google Scholar 

  • Blum, M.D., Graham, D.J., and McCloskey, C.A., 1994, Temafloxacin syndrome, Clin. Infect. Dis 18:946–950.

    Article  PubMed  CAS  Google Scholar 

  • Bonierbale, E., Valadon, P., Pous, C., Desfosses, B., Dansette, P.M., and Mansuy, D., 1999, Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds, Chem. Res. Toxicol 12:286–296.

    Article  PubMed  CAS  Google Scholar 

  • Boyd, M.R., Catignani, G.L., Sasame, H.A., Mitchell, J.R., and Stiko, A.W., 1979, Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat and oxygen, Am. Rev. Respir. Dis 120: 93.

    PubMed  CAS  Google Scholar 

  • Bretza, J.A. and Novey, H.S., 1985, Anaphylactoid reactions to tolmetin after interrupted dosage, Western J. Med 143:55–59.

    CAS  Google Scholar 

  • Brodie, B.B., Reid, W.D., Cho, A.K., Sipes, G., Krishna, G., and Gillette, J.R., 1971, Possible mechanism of liver necrosis caused by aromatic organic compounds, Proc. Natl. Acad. Sci. U.S.A 68: 160–164.

    Article  PubMed  CAS  Google Scholar 

  • Chatterjee, G.P., 1981, Nephrotic syndrome with Tolmetin, J. Amer. Med. Assoc 246 1589.

    Article  CAS  Google Scholar 

  • Chen, H.J.L., Bloch, K.J., and MacLean, J.A., 2000, Acute eosinophilic hepatitis from trovofloxacin, N. Engl. J. Med 342:359–360.

    Article  PubMed  CAS  Google Scholar 

  • Clive, D.M., and Stoff, J.F., 1984, Renal syndromes associated with non-steroidal anti-inflammatory drugs, N. Engl. J. Med 310:563–572.

    Article  PubMed  CAS  Google Scholar 

  • Cribb, A.E., and Spielberg, S.P., 1992, Sulfamethoxazole is metabolized to the hydroxylamine in humans, Clin. Pharmacol. Ther 51:522–526.

    Article  PubMed  CAS  Google Scholar 

  • Dalvie, D.K., Khosla, N., and Vincent, J., 1997, Excretion and metabolism of trovofloxacin in humans, Drug Metab. Dispos 25:423–427.

    PubMed  CAS  Google Scholar 

  • Fischer, V., Haar, J.A., Greiner, L., Lloyd, R.V., and Mason, R.P., 1991, Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis, Mol. Pharmacol 40:846–853.

    PubMed  CAS  Google Scholar 

  • Forman, L.M., Simmons, D.A., and Diamond, R.H., 2000, Hepatic failure in a patient taking rosiglitazone, Ann. Intern. Med 132:118–121.

    PubMed  CAS  Google Scholar 

  • Fouda, H.G., Avery, M.J., Dalvie, D., Falkner, F.C., Melvin, L.S., and Ronfeld, R.A., 1997, Disposition and metabolism of tenidap in the rat, Drug Metab. Dispos 2525 140–148.

    PubMed  CAS  Google Scholar 

  • Friedman, M.A., Woodcock, J., Lumpkin, M.M., Shuren, J.E., Hass, A.E., and Thompson, L.J., 1999, The safety of newly approved medicines: Do recent market removals mean there is a problem?, J. Amer. Med. Assoc 281: 1728–1734.

    Article  CAS  Google Scholar 

  • Gardner, I., Zahid, N., MacCrimmonD.and Uetrecht, J.P., 1998, Comparison of the oxidation of clozapine and olanzapine to active metabolites and the toxicity of these metabolites to human leukocytes, Mol. Pharmacol 53:991–998.

    PubMed  CAS  Google Scholar 

  • Gheyi, S.K., Robertson, A., and Atkinson, P.M., 1999, Severe interstitial cystitis caused by tiaprofenic acid, J. Royal Soc. Med 92: 17.

    CAS  Google Scholar 

  • Gometz, J.L., Dupont, A., Cusan, L., Tremblay, M., and Labrie, F., 1992, Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): A case report, Am. J. Med 92:563–566.

    Article  Google Scholar 

  • Hargus, S.J., Amouzedeh, H.R., Pumford, N.R., Myers, T.J., McCoy, S.C., and Pohl, L.R., 1994, Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac, Chem. Res. Toxicol 7:575–582.

    Article  PubMed  CAS  Google Scholar 

  • Hess, D.A., Sisson, M.E., Suria, H., Wijsman, J., Puvanesasingham R. Madrenas, J., and Reider, M.J., 1999, Cytotoxicity of sulfonamide reactive metabolites: Apoptosis and selective toxicity of CD8+ cells by the hydroxylamine of sulfamethoxazole, FASEB J 13: 1688–1698.

    PubMed  CAS  Google Scholar 

  • Holmberg, L., Roman, G., Bottiger, L.E., Eriksson, B., Spross, R., and Wessling, A., 1980, Adverse reactions to nitrofurantoin, Am. J. Med 69:733–738.

    Article  PubMed  CAS  Google Scholar 

  • Jaunkalns, R., Shear, N.H., Sokoluk, B., Gardner, D., Claas, F., and Uetrecht, J.P., 1992, Antimyeloperoxidase antibodies and adverse reactions to clozapine, Lancet 339: 1611–1612.

    Article  PubMed  CAS  Google Scholar 

  • Kassahun, K., Mattiuz, E., Nyhart, E., ObermeyerB Gillespie, T., Murphy, A., Goodwin, R.M., Tupper, T., Callaghan, J.T., and Lemberger, L., 1997, Disposition and biotransformation of the antipsychotic agent olanzapine in humans, Drug Metab. Dispos 25:81–93.

    PubMed  CAS  Google Scholar 

  • Kretz-Rommel, A., and Boelsterli, U.A., 1993, Diclofenac covalent protein binding is dependent on acyl glucuronide fomation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes Toxicol. Appl. Pharmacol 120: 155–161.

    Article  PubMed  CAS  Google Scholar 

  • Liu, X.C., and Uetrecht, J.P., 2000, Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis, Drug Metab. Dispos 28:726–730.

    PubMed  CAS  Google Scholar 

  • Maggs, J.L., Williams, D., Pirmohamed, M., and Park, B.K., 1995, The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man, J. Pharmacol. Exp. Ther 275: 1463–1475.

    PubMed  CAS  Google Scholar 

  • Naumann, R., Felber, W., Heilemann, H., and Reuster, T., 1999, Olanzapine-induced agranulocytosis, Lancet 354:566–567.

    Article  PubMed  CAS  Google Scholar 

  • Nelson, S.D., 1982, Metabolic activation and drug toxicity, J. Med. Chem 25:753–765.

    Article  PubMed  CAS  Google Scholar 

  • Ono, K., Kurohara, K., Yoshihara, M., Shimamoto, Y., and Yamaguchi, M., 1991, Agranulocytosis caused by ticlopidine and its mechanism, Am. J. Hematol 37:239–242.

    Article  PubMed  CAS  Google Scholar 

  • Peruzzi, L., Gianoglio, B., Porcellini, M.G., and Coppo, R., 1999, Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic, Lancet 354:1615.

    Article  PubMed  CAS  Google Scholar 

  • Pfitzenmeyer, P., Feucher, P., and Piard, F., 1992, Nilutamide pneumonitis: A report of eight patients, Thorax 47:622–627.

    Article  PubMed  CAS  Google Scholar 

  • Pirmohamed, M., Madden, S., and Bark, B.K., 1996, Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism, Clin. Pharmacokin 31:215–230.

    Article  CAS  Google Scholar 

  • Reinhart, H.H., Reinhart, E., Korlipara, P., and Peleman, R., 1992, Combined nitrofurantoin toxicity to liver and lung, Gastroenterology 102:1396–1399.

    PubMed  CAS  Google Scholar 

  • Rombach, E.M., and Hanzlik, R.P., 1999, Detection of adducts of bromobenzene 3,4-oxide with rat liver microsomal protein sulthydryl groups using specific antibodies, Chem. Res. Toxicol 12:159–163.

    Article  PubMed  CAS  Google Scholar 

  • Rubin, R.L., 1989, Autoimmune reactions induced by procainamide and hydralazine, in: Autoimmunity and Toxicology (M.E. Kammüller, N. Bloksma, and W. Seinen, eds.), Elsevier Science Publishers, New York, pp. 119–150.

    Google Scholar 

  • Samuel, S.A., 1981, Apparent anaphylactic reaction to zomepirac (Zomax), N. Engl. J. Med 304:978.

    PubMed  CAS  Google Scholar 

  • Sarosdy, M.F., 1999, Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first-to second-generation antiandrogen, Anti-cancer Drugs 10:791–796.

    Article  PubMed  CAS  Google Scholar 

  • SCRIP, No. 2073, October 31, 1995, p. 21.

    Google Scholar 

  • Shaw, G.R. and Anderson, R.W., 1991, Multisystem failure and hepatic microvesicular fatty metamorphosis associated with tolmetin ingestion, Arch. Pathol. Lab. Med 115:818–821.

    PubMed  CAS  Google Scholar 

  • Shen, S., Marchick, M.R., Davis, M.R., Doss, G.A., and Pohl, L.R., 1999, Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac, Chem. Res. Toxicol 12:214–222.

    Article  PubMed  CAS  Google Scholar 

  • Silva, J.M., Khan, S., O’Brien, P.W., 1993, Molecular mechanisms of nitrofurantoin-induced hepatocyte toxicity in aerobic versus hypoxic conditions, Arch. Biochem. Biophys 305:362–369.

    Article  PubMed  CAS  Google Scholar 

  • Spahn-Langguth, H., and Benet, L.Z., 1992, Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as detoxification mechanism?, Drug Metab. Rev 24:5–48.

    Article  PubMed  CAS  Google Scholar 

  • Tang, W., Stearns, R.A., Wang, R.W., Chin, S.H.L., and Baillie, T.A., 1999, Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac, Chem. Res. Toxicol 12: 192–199.

    Article  PubMed  CAS  Google Scholar 

  • The Pink Sheet, March 27, 2000, p.4.

    Google Scholar 

  • Tietjen, D.P., 1989, Recurrence and specificity of nephrotic syndrome due to tolmetin, Am. J. Med 87:354–355.

    Article  PubMed  CAS  Google Scholar 

  • Tsatalas, C., Chalkia, P., Garyfallos, A., KakoulidisI and Xanthakis, I., 1995, Ticlopidine-induced aplastic anemia: Case report and review of the literature, Clin. Drug Invest 9: 127–130.

    Article  Google Scholar 

  • Uetrecht, J., 1990, Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions, Crit. Rev. Toxicol 20:213–235.

    Article  PubMed  CAS  Google Scholar 

  • U.S. Congress, 1982, Committee on Government Operations, Intergovemment Relations and Human Resources:FDA’s regulation of Zomax, Proceedings of the Ninety-eighth Congress, Washington, D.C.

    Google Scholar 

  • Warren, S.E., and Mosley, C., 1983, Renal failure and tubular dysfunction due to zomepirac therapy, J. Amer. Med. Assoc 249:396–398.

    Article  CAS  Google Scholar 

  • Wysowski D. and Fourcroy, J., 1996, Flutamide hepatotoxicity, J. Urol 155:209–212.

    Article  PubMed  CAS  Google Scholar 

  • Yamazaki, H., Shibata, A., Suzuki, M., Nakajima, M., Shimada, N., Guengerich, F.P., and Yokoi, T., 1999, Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes, Drug Metab. Dispos 27:1260–1266.

    PubMed  CAS  Google Scholar 

  • Zimmerman, H.J., Lewis, J.L., Ishak, K.G., and Maddrey, W.C., 1984, Ticrynafen-associated hepatic injury: Analysis of 340 cases, Hepatology 4:315–323.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, University of Washington, Box 357631, Seattle, WA, 98195-7631, USA

    Sidney D. Nelson

Authors
  1. Sidney D. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Université René Descartes, Paris, France

    Patrick M. Dansette

  2. Rutgers University and The Environmental & Occupational Health Sciences Institute, Piscataway, New Jersey, USA

    Robert Snyder

  3. CNRS, Paris, France

    Marcel Delaforge

  4. University of Surrey, Guildford, Surrey, England

    G. Gordon Gibson

  5. Institute of Toxicology and Environmental Health, The Technical University of Munich, Munich, Germany

    Helmut Greim

  6. Medical University of South Carolina, Charleston, South Carolina, USA

    David J. Jollow

  7. University of Texas, Austin, Texas, USA

    Terrence J. Monks

  8. University of Arizona, Tucson, Arizona, USA

    I. Glenn Sipes

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nelson, S.D. (2001). Structure Toxicity Relationships - How Useful Are They in Predicting Toxicities of New Drugs?. In: Dansette, P.M., et al. Biological Reactive Intermediates VI. Advances in Experimental Medicine and Biology, vol 500. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0667-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0667-6_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5185-6

  • Online ISBN: 978-1-4615-0667-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation